No new diabetes drug approval, label change or safety communication appeared in today's sweep. The most recent regulatory activity was a batch of routine labelling supplements dated 11 August to metformin combination products already long on the market, together with a supplement to sotagliflozin on 6 August. None carries a new indication in the record, and none is new today. A quiet day is a quiet day.
The substantive change is a guideline, not an approval. The 2026 American Heart Association, American College of Cardiology and multisociety dyslipidaemia guideline issued new recommendations on how atherosclerotic cardiovascular disease risk is estimated and on who should be offered a statin for primary prevention. An analysis of the US National Health and Nutrition Examination Survey from 2017 to 2023, covering 4,366 adults aged 30 to 79 without known cardiovascular disease and representing 154.5 million people, put numbers on what that means. Under the new guideline, 87.5 million adults (56.6%, 95% CI 54.2-58.9) are statin-eligible, of whom 21.5 million (13.9%, 95% CI 12.5-15.5) are newly so. Eligibility is now above 93% for those aged 70 to 79 and 85% for those aged 60 to 69, against 11% for those aged 30 to 39.
For a diabetologist, the important detail is what did not change. Diabetes, chronic kidney disease and an untreated LDL (low-density lipoprotein) cholesterol of 190 mg/dL or above still make someone statin-eligible without any risk calculation at all; that group made up 8.6% of the sample. The expansion falls on the 68% whose decision depends on a risk estimate, which in practice means your non-diabetic primary prevention clinic and your patients' relatives, not your diabetes list. It is also worth noting that these are US population figures, and that a risk equation calibrated to that population will tend to underestimate risk in a younger, lower-BMI, higher-prevalence Indian population. RSSDI (Research Society for the Study of Diabetes in India) guidance already treats diabetes as reason enough to treat lipids on its own terms, and this analysis does not change that.
- Do not reopen statin decisions in patients with diabetes on the strength of this; diabetes was and remains an indication independent of risk scoring
- Expect more statin questions from non-diabetic family members attending with your patients, particularly those in their sixties and seventies
- Where a risk calculator is used in Indian practice, treat its output as a floor rather than an estimate, given the younger age at onset
- Record an untreated LDL cholesterol value where one exists; the 190 mg/dL threshold still bypasses risk estimation entirely
- Check for a documented statin intolerance rather than assuming non-prescription means contraindication when reviewing an older patient not on treatment
The statistics, in plain English
The newly eligible group has a mean estimated 10-year cardiovascular risk of 3.1% (95% CI 2.7-3.5) against 6.1% (95% CI 5.8-6.4) for those already eligible, so the guideline extends treatment to people at roughly half the risk of the existing group. That matters because absolute benefit falls with baseline risk: the same relative risk reduction from a statin prevents fewer events per hundred people treated in a lower-risk group, so the number needed to treat rises even though the drug works just as well. These are survey-weighted proportions, meaning 4,366 people were scaled to represent 154.5 million, which is why the confidence intervals are wider than the raw sample size would suggest. All figures describe eligibility, not prescriptions; only 17.8% of the sample reported actually taking a statin.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free